Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone973-242-0005
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
Neurotrope (NASDAQ:NTRP) Frequently Asked Questions
What is Neurotrope's stock symbol?
Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."
How were Neurotrope's earnings last quarter?
Neurotrope Inc (NASDAQ:NTRP) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.31) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.38) by $0.07. View Neurotrope's Earnings History.
When is Neurotrope's next earnings date?
What price target have analysts set for NTRP?
2 equities research analysts have issued 12 month price objectives for Neurotrope's shares. Their forecasts range from $1.00 to $16.00. On average, they anticipate Neurotrope's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 1,164.9% from the stock's current price. View Analyst Price Targets for Neurotrope.
What is the consensus analysts' recommendation for Neurotrope?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neurotrope.
What are Wall Street analysts saying about Neurotrope stock?
Here are some recent quotes from research analysts about Neurotrope stock:
- 1. According to Zacks Investment Research, "Neurotrope, Inc. is focused primarily on the development and commercialization of Alzheimer's disease therapeutic products related diagnostics. The Company develops and markets two product platforms, including a non-invasive diagnostic test for Alzheimer's disease and a drug candidate called bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage. Neurotrope, Inc. is based in Plantation, Florida. " (10/10/2019)
- 2. Maxim Group analysts commented, "Neurotrope announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of Bryostatin-1 in acute lymphoblastic leukemia (ALL)." (2/5/2019)
Has Neurotrope been receiving favorable news coverage?
Media stories about NTRP stock have trended negative recently, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neurotrope earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Neurotrope.
Are investors shorting Neurotrope?
Neurotrope saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 236,300 shares, a decline of 57.6% from the August 30th total of 557,100 shares. Based on an average daily volume of 508,700 shares, the days-to-cover ratio is currently 0.5 days. Approximately 2.4% of the company's stock are sold short. View Neurotrope's Current Options Chain.
Who are some of Neurotrope's key competitors?
Some companies that are related to Neurotrope include Sernova (SEOVF), Jaguar Health (JAGX), Adamis Pharmaceuticals (ADMP), Bellerophon Therapeutics (BLPH), Acer Therapeutics (ACER), China SXT Pharmaceuticals (SXTC), Clearside Biomedical (CLSD), Zosano Pharma (ZSAN), Addex Therapeutics (ADDXF), Leap Therapeutics (LPTX), Fibrocell Science (FCSC), DiaMedica Therapeutics (DMAC), Aptevo Therapeutics (APVO), Zafgen (ZFGN) and Bio-Path (BPTH).
What other stocks do shareholders of Neurotrope own?
Who are Neurotrope's key executives?
Neurotrope's management team includes the folowing people:
- Dr. Charles S. Ryan, CEO & Director (Age 55)
- Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)
- Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)
- Dr. Michael Ciraolo, Gen. Counsel & COO (Age 46)
- Mr. Jeffrey Benison, Director of Corp. Communications
How do I buy shares of Neurotrope?
Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Neurotrope's stock price today?
One share of NTRP stock can currently be purchased for approximately $0.67.
How big of a company is Neurotrope?
Neurotrope has a market capitalization of $8.75 million. The company earns $-11,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Neurotrope employs 6 workers across the globe.View Additional Information About Neurotrope.
What is Neurotrope's official website?
How can I contact Neurotrope?
Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]
MarketBeat Community Rating for Neurotrope (NASDAQ NTRP)
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
